A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects

Trial Profile

A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Lumicitabine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 29 Jun 2017 Status changed from recruiting to completed.
    • 31 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
    • 31 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top